235 related articles for article (PubMed ID: 37657358)
1. Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinoma.
Huang J; Zhang J; Zhang F; Lu S; Guo S; Shi R; Zhai Y; Gao Y; Tao X; Jin Z; You L; Wu J
Comput Biol Med; 2023 Oct; 165():107402. PubMed ID: 37657358
[TBL] [Abstract][Full Text] [Related]
2. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis.
Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L
Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890
[TBL] [Abstract][Full Text] [Related]
3. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
Wang Y; Xu Y; Liu C; Yuan C; Zhang Y
Front Immunol; 2023; 14():1233260. PubMed ID: 37799714
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma.
Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G
Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
6. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
7. Identifying and assessing a prognostic model based on disulfidptosis-related genes: implications for immune microenvironment and tumor biology in lung adenocarcinoma.
Wang J; Liu K; Li J; Zhang H; Gong X; Song X; Wei M; Hu Y; Li J
Front Immunol; 2024; 15():1371831. PubMed ID: 38840910
[TBL] [Abstract][Full Text] [Related]
8. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
Aging (Albany NY); 2024 Jun; 16():. PubMed ID: 38862217
[TBL] [Abstract][Full Text] [Related]
9. Investigating the prognostic value of constructing disulfidptosis-related gene models for lung adenocarcinoma patients.
Luo M; Liu RZ; Li YJ; Zhang SD; Wu ZY
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9569-9585. PubMed ID: 37916324
[TBL] [Abstract][Full Text] [Related]
10. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
11. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
12. The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-associated genes in lung adenocarcinoma.
Qi C; Ma J; Sun J; Wu X; Ding J
Aging (Albany NY); 2023 Jun; 15(11):5075-5095. PubMed ID: 37315289
[TBL] [Abstract][Full Text] [Related]
13. A New Prognostic Indicator of Immune Microenvironment and Therapeutic Response in Lung Adenocarcinoma Based on Peroxisome-Related Genes.
Xiong Z; Zhang L; Fan W
J Immunol Res; 2022; 2022():6084589. PubMed ID: 35935579
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of single-cell and bulk RNA-sequencing data revealed disulfidptosis genes-based molecular subtypes and a prognostic signature in lung adenocarcinoma.
Wang H; Zhu X; Zhao F; Guo P; Li J; Du J; Shan G; Li Y; Li J
Aging (Albany NY); 2024 Feb; 16(3):2753-2773. PubMed ID: 38319721
[TBL] [Abstract][Full Text] [Related]
15. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma.
Zhang HB; Pan JY; Zhu T
Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882
[No Abstract] [Full Text] [Related]
16. Elaboration and validation of a prognostic signature associated with disulfidoptosis in lung adenocarcinoma, consolidated with integration of single-cell RNA sequencing and bulk RNA sequencing techniques.
He D; Tang H; Yang X; Liu X; Zhang Y; Shi J
Front Immunol; 2023; 14():1278496. PubMed ID: 37965333
[TBL] [Abstract][Full Text] [Related]
17. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
19. Application of Cytochrome C-Related Genes in Prognosis and Treatment Prediction of Lung Adenocarcinoma.
Tang M; Li G; Chen L; Tu J
Dis Markers; 2022; 2022():8809956. PubMed ID: 36225197
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
